Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Asieris Pharmaceuticals
AddedJul 2, 2026
UpdatedJul 2, 2026
Asieris Pharmaceuticals

Asieris Pharmaceuticals

Series D

Asieris Pharmaceuticals is a global biopharma company specializing in the R&D of new drugs for genitourinary tumors and women's health.

HQ
Shanghai, Shanghai, CN
Founded
2010
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Asieris Pharmaceuticals (688176.SH), founded in March 2010 in China Medical City, Jiangsu Taizhou with R&D in Shanghai, is a global innovative biopharma company specializing in discovering, developing and commercializing innovative drugs for genitourinary tumors and related diseases as well as women's health.

The company integrates R&D, manufacturing and commercialization to provide best-in-class integrated diagnosis and treatment solutions. Flagship products include Vesique (APL-1202) for bladder cancer and Cevira (APL-1702), the world's first non-invasive photodynamic therapy for cervical precancerous lesions, recently approved and launching in China. It is a Qiming Venture Partners portfolio company and publicly listed on the Shanghai STAR Market.

Asieris Pharmaceuticals - Similar Companies

Aria Pharmaceuticals logo

Aria Pharmaceuticals

Arisaph Pharmaceuticals logo

Arisaph Pharmaceuticals

Asher Bio logo

Asher Bio

asherbio.com

CASI Pharmaceuticals logo

CASI Pharmaceuticals

UE LifeSciences logo

UE LifeSciences

uelifesciences.com

Sisu Pharma logo

Sisu Pharma

sisupharma.com

Blueprint Medicines logo

Blueprint Medicines

Abvc Biopharma logo

Abvc Biopharma

Zai Lab logo

Zai Lab

zailaboratory.com

Ariz Precision Medicine logo

Ariz Precision Medicine

arizbio.com

Novita Pharmaceuticals logo

Novita Pharmaceuticals

novita-pharm.com

Kira Pharmaceuticals logo

Kira Pharmaceuticals

kirapharma.com

Tigris Pharmaceuticals logo

Tigris Pharmaceuticals

tigrispharma.com

Elevar Therapeutics logo

Elevar Therapeutics

Artisan Pharma logo

Artisan Pharma

Asieris Pharmaceuticals - Quick Facts

Who are Asieris Pharmaceuticals' competitors?

Companies similar to Asieris Pharmaceuticals include Aria Pharmaceuticals, Arisaph Pharmaceuticals, Asher Bio and CASI Pharmaceuticals.

When was Asieris Pharmaceuticals founded?

Asieris Pharmaceuticals was founded in 2010.

Where is Asieris Pharmaceuticals' headquarters located?

Asieris Pharmaceuticals' headquarters is located in Shanghai, Shanghai, CN.

When was Asieris Pharmaceuticals' last funding round?

Asieris Pharmaceuticals' most recent funding round was for $108M (USD) in November 2020.

How much has Asieris Pharmaceuticals raised to-date?

As of Nov 11, 2020, Asieris Pharmaceuticals has raised a total of $498M (USD).

Asieris Pharmaceuticals - Classification

Tags
  • Biotechnology
  • Healthcare
  • Oncology
  • Pharmaceuticals
  • Public Company